A B ST R A CT The binding of '251-von Willebrand factor to platelets stimulated by thrombin, ADP, and a combination of ADP + epinephrine (EPI) is specific, saturable, and reversible. Active platelet metabolism and divalent cations are required for binding induced by these stimuli, but not by ristocetin, suggesting the existence of different mechanisms involved in the vWF-platelet interaction. A monoclonal antibody directed against an epitope of membrane glycoprotein (GP) lb had no effect on the binding of '251-vWF to normal platelets stimulated by thrombin or a combination of ADP + EPI, but completely blocked ristocetin-induced binding. Binding induced by thrombin to GPIb-blocked platelets was specific. Moreover, thrombin-induced binding of 1251-vWF was increased, rather than decreased, in two patients with the Bernard-Soulier syndrome whose platelets lacked GPIb. Conversely, monoclonal antibodies directed against the GPIIb/IIIa complex had no effect on ristocetininduced binding of (vWF)' is a large multimeric glycoprotein that circulates in blood complexed with the Factor VIII procoagulant activity protein (1). It plays an essential role in platelet function as shown by the prolonged bleeding time in von Willebrand disease (1). Specific binding sites for vWF are induced on the platelet membrane by the antibiotic ristocetin (2), a nonphysiologic agent, as well as by thrombin (3, 4) and ADP (5). Platelet membrane glycoprotein (GP) lb is considered to function as the surface receptor for vWF (6). In the Bernard-Soulier syndrome, a congenital bleeding disorder, platelets lack GPIb (7) and the ristocetin-induced binding of vWF is decreased (8). On the other hand, in Glanzmann thrombasthenia, another congenital platelet abnormality, there is a marked decrease of the membrane GP complex Ilb/Illa but normal content of GPIb (9). The ristocetin-induced binding of vWF to thrombasthenic platelets has been reported to be normal (8). In contrast, we have recently shown that binding of vWF to thrombasthenic platelets stimulated by thrombin is severely deficient (4). Therefore, we postulated that different sites are involved in ' Abbreviations used Marguerie et al. (12). The final platelet suspensions were all in modified calcium-free Tyrode buffer, containing 137 mM NaCI, 2 mM MgCI2, 0.42 mM NaH2PO4, 11.9 mM NaHCO3, 2.9 mM KCI, 5.5 mM glucose, 10 mM Hepes, pH 7.35, and 20 mg/ml bovine serum albumin (Fraction V, CalbiochemBehring Corp., American Hoechst Corp., San Diego, CA). When experiments of serotonin release were performed, PRP was labeled before washing by incubating 20 ml with 0. (3.3,M). However, ADG-washed platelets usually gave reversible aggregation to ADP and were unresponsive to epinephrine (EPI). On the contrary, gel-filtered platelets always gave irreversible aggregation to ADP, and responded to 20 MM EPI in the presence of fibrinogen (3.3 ,M) with a typical two-wave aggregation. Contamination of plasma vWF in all washed platelet preparations was below 5 X 10' U/dl (1 dl of a normal plasma pool contains 1 X 102 U) as measured by immunoradiometric assay (13) . No agglutination of washed platelets occurred in response to the addition of ristocetin (1.5 mg/ml) unless vWF was added to the suspension.
INTRODUCTION
von Willebrand factor (vWF) ' is a large multimeric glycoprotein that circulates in blood complexed with the Factor VIII procoagulant activity protein (1) . It plays an essential role in platelet function as shown by the prolonged bleeding time in von Willebrand disease (1) . Specific binding sites for vWF are induced on the platelet membrane by the antibiotic ristocetin (2) , a nonphysiologic agent, as well as by thrombin (3, 4) and ADP (5) . Platelet membrane glycoprotein (GP) lb is considered to function as the surface receptor for vWF (6) . In the Bernard-Soulier syndrome, a congenital bleeding disorder, platelets lack GPIb (7) and the ristocetin-induced binding of vWF is decreased (8) . On the other hand, in Glanzmann thrombasthenia, another congenital platelet abnormality, there is a marked decrease of the membrane GP complex Ilb/Illa but normal content of GPIb (9) . The ristocetin-induced binding of vWF to thrombasthenic platelets has been reported to be normal (8) . In contrast, we have recently shown that binding of vWF to thrombasthenic platelets stimulated by thrombin is severely deficient (4) . Therefore, we postulated that different sites are involved in 1 the binding of vWF induced by different stimuli (4) . In this report we provide evidence to confirm that hypothesis.
METHODS
Patients and controls. Two patients fulfilled all the accepted criteria for the diagnosis of the Bernard-Soulier syndrome. They have been extensively characterized in a previous report (10) . Blood from the two patients was drawn by Dr. Margaret Johnson at Wilmington Medical Center, Delaware, and shipped overnight to Milwaukee, where experiments with Bernard-Soulier platelets were performed. Blood from a normal control was drawn at the same time and shipped similarly. All other experiments were performed in Milan, using fresh blood from normal volunteers. All subjects were aware of the experimental nature of these studies and gave their informed consent, according to the Declaration of Helsinki. They reported no intake of any drug for the week preceding the studies.
Preparation of washed platelets. Blood was drawn through 19 -gauge needles into polypropylene syringes as one part of acid/citrate/dextrose to five parts of blood and immediately transferred into polypropylene tubes. Platelet-rich plasma (PRP) of the Bernard-Soulier patients and the normal control studied at the same time was separated from whole blood by layering on top of a solution made of two parts of dextran (4%, average Mr 500,000; Sigma Chemical Co., St . Louis, MO) and one part of sodium metrizoate (32.8% wt/vol aqueous solution; Sigma Chemical Co.). Erythrocytes settled out in -60-90 min, and the PRP remaining on top of the dextran-sodium metrizoate solution was carefully removed. Only the upper two-thirds were used to minimize leukocyte contamination. PRP for all other experiments was obtained by three successive differential centrifugation steps at 1,200 g for 60 s. Each time PRP was removed and the blood recentrifuged without mixing. Platelets were washed free of plasma constituents by one or both of two methods, the albumin density-gradient (ADG) technique of Walsh et al. (11) , or the gel-filtration technique described by Marguerie et al. (12) . The final platelet suspensions were all in modified calcium-free Tyrode buffer, containing 137 mM NaCI, 2 mM MgCI2, 0.42 mM NaH2PO4, 11.9 mM NaHCO3, 2.9 mM KCI, 5.5 mM glucose, 10 mM Hepes, pH 7.35, and 20 mg/ml bovine serum albumin (Fraction V, CalbiochemBehring Corp., American Hoechst Corp., San Diego, CA). When experiments of serotonin release were performed, PRP was labeled before washing by incubating 20 (3.3,M) . However, ADG-washed platelets usually gave reversible aggregation to ADP and were unresponsive to epinephrine (EPI). On the contrary, gel-filtered platelets always gave irreversible aggregation to ADP, and responded to 20 MM EPI in the presence of fibrinogen (3.3 ,M) with a typical two-wave aggregation. Contamination of plasma vWF in all washed platelet preparations was below 5 X 10' U/dl (1 dl of a normal plasma pool contains 1 X 102 U) as measured by immunoradiometric assay (13) . No agglutination of washed platelets occurred in response to the addition of ristocetin (1.5 mg/ml) unless vWF was added to the suspension.
Preparation of apyrase. Apyrase was prepared by the method of Molnar and Lorand (14) . It was finally dissolved in 0.15 M NaCl, and stored at -20°C until used. At a concentration of 9 ,Ml/ml, it caused 93% conversion of 9 MM ADP to AMP and adenosine in 2 min at 370C. Creatine phosphate and creatine phosphokinase were obtained from Sigma Chemical Co.
Purification of vWF. For a typical preparation, 20-30 bags of human plasma cryoprecipitate prepared by the method of Pool et al. (15) were resuspended at 37°C in 200 ml of a buffer consisting of 20 mM Tris, 20 mM sodium citrate (tribasic), 20 mM E-aminocaproic acid, pH 7, containing 0.5 mM phenylmethylsulfonyl fluoride (PMSF). The redissolved cryoprecipitate was then adsorbed with Al(OH)3 (16) . The further purification steps were performed according to Newman et al. (17) , as modified by Switzer and McKee (18) . Gel filtration was performed on a 5 X 80-cm column of Sepharose CL-4B (Pharmacia Fine Chemicals, Uppsala, Sweden) equilibrated with a buffer consisting of 20 mM imidazole, 100 mM NaCl, 10 mM sodium citrate (tribasic), 20 mM EACA, pH 6.5, and containing PMSF as indicated. vWF was present in the void volume protein peak along with Factor VIII procoagulant activity (VIII:C). The fractions corresponding to the ascending part of the peak were pooled and concentrated by dialysis against polyethylene glycol (average Mr = 40,000). The vWF preparations used in these experiments had a protein concentration of between 0.56 and 0.78 mg/ ml and a specific activity of 116-128 U of ristocetin cofactor activity, 117-135 U of Factor VIII-related antigen, and 47-52 U of VIII:C/mg of protein. The purity of the final product was assessed by electrophoresis in 5% acrylamide-0.25% bisacrylamide disc gels, containing sodium dodecyl sulfate (SDS), after reduction of the protein by dithiothreitol (19) . Some preparations of purified vWF were also treated with rabbit anti-human fibrinogen IgG coupled to Sepharose 4B-CL beads to remove trace contamination of fibrinogen. The procedure used was that recently described by Fujimoto et al. (3) . The antiserum used was obtained from Beheringwerke (Scopitto, Italy). Fibrinogen contamination was evaluated by specific radioimmunoassay (kindly performed by Dr. Edward F. Plow, Scripps Clinic and Research Foundation).
Radioiodination of purified vWF. This was accomplished with 125I by the method of Fraker and Speck (20) to a specific activity of between 0.48 and 0.89 mCi/mg. The preparations of '251-vWF were characterized by electrophoretic analysis in SDS agarose gels as described (21) .
Preparation of monoclonal antibodies. BALB/c female mice were given a primary intraperitoneal immunization with I X 109 washed platelets (albumin was omitted from the platelet suspension in this case) in 0.5 ml of Freund's complete adjuvant. Three subsequent intraperitoneal immunizations with 1 X 109 washed platelets suspended in 0.9% saline were given at 2-wk intervals. 1 wk after the last injection, the mice were given 2 X 109 platelets intravenously. 4 d later the mice were killed and their spleen cells used for fusion. Hybridization was carried out using 2.5 x 108 spleen cells mixed at a 1:1 ratio with P3-x-63Ag8-653 (nonsecretor) myeloma cells, according to the method of Oi and Herzenburg (22) , using 50% polyethylene glycol 1500. Positive hybridomas were selected using partially purified platelet membrane glycoproteins (GPIIb/IIIa complex and GPIb), as well as a microtiter screening assay for the inhibition of ristocetininduced platelet aggregation (23 Characterization of monoclonal antibodies. The specificity of monoclonal antibodies to platelet membrane glycoproteins was assessed after radiolabeling with 125I by the chloramine-T method (24). The radiolabeled antibodies were then used in the second dimension of crossed immunoelectrophoresis mixed with unlabeled rabbit antiplatelet antisera (25) . Triton X-100-solubilized platelets were electrophoresed in the first dimension. The immunologic reactivity of the monoclonal antibodies was substantiated by identification of the platelet membrane glycoprotein immunoprecipitate patterns (26) . Alternatively, platelet membranes were radiolabeled with 125I by the lactoperoxidase method (9) 30 and 40 min (Fig. 2) . The binding to unstimulated platelets corresponded to that observed with each one of the stimuli when a 50-fold excess (wt/wt) of unlabeled vWF was added to the platelet suspension before 1251_ vWF. Therefore, nonspecific binding was the same with all stimuli, and accounted for only a minor fraction of the total '251-vWF bound to stimulated platelets.
When ristocetin (1.5 mg/ml final concentration) was used as a stimulus, the results obtained were comparable to those previously reported by others (2) .
Specific binding induced by thrombin, ADP, or ADP + EPI was blocked by 5 with formalin-fixed platelets. However, bindi-ng induced by ristocetin was observed using formalin-fixed platelets and in the presence of EDTA. '251vWF Added 1% of Total) FIGURE 3 Relative binding of '25I-vWF and unlabeled vWF to thrombin-stimulated platelets. The total vWF concentration in the mixtures was kept constant (12 Mg/ml), but the proportion of labeled and unlabeled vWF was varied as indicated. Platelets were stimulated with 0.25 U/ml of thrombin and binding was measured after incubation for 30 Effect of agonist concentration on 125I-vWF binding and platelet release reaction. The relationship between the dose of each stimulus required to support '251-vWF binding and induce platelet release of ["4C]-serotonin was investigated using thrombin-, ADP-, or ADP + EPI-stimulated platelets (Fig. 4) . When thrombin was used, specific binding occurred in parallel with the release reaction. Thrombin concentrations as low as 0.0125 U/ml were effective in this regard. A plateau in the thrombin dose-response curve was observed at 0.5 U/ml, with no further increase in binding at concentrations as high as 2 U/ml (Fig. 4) . Thrombin stimulation of platelets followed by thrombin neutralization with a fourfold (U/U) excess of hirudin (obtained from Pentapharma, Basel, Switzerland) before addition of the radioligand resulted in binding similar to that observed with thrombin and radioligand added simulta- (Fig. 4) . Similar results were obtained with the addition of creatine phosphate (7.5 mM) and creatine phosphokinase (12 U/ml) instead of apyrase. At variance with thrombin, ADP-or ADP + EPI-induced binding was independent of the platelet release reaction. The latter was not observed with these two stimuli under the experimental conditions used (Fig. 4) . The dose-dependency of ristocetin-induced binding was comparable to that previously reported by others (2). Specificity of binding. Competition experiments were performed to demonstrate the specificity of the association of '251-vWF to thrombin-stimulated platelets. As shown in Table I , human fibronectin, transferrin, and IgM at >100-fold excess (wt/wt) were not effective in displacing the binding of '251-vWF significantly. In addition, the serum from three patients with severe von Willebrand disease (Factor VIII-related antigen in plasma < 1 X 10-4 U/ml) had a minimal effect on binding of '251-vWF, whereas serum from three normal individuals had an inhibitory effect (Table I).
Dissociation of bound 1251-vWF from platelets.
The capacity of unlabeled vWF to displace '251-vWF bound to thrombin-stimulated platelets was analyzed. Displacement of bound '251-vWF was dependent upon the time of addition of unlabeled vWF (Fig. 5) . When a 50-fold excess (wt/wt) of the latter was added before (Fig. 5) . When excess unlabeled vWF was added to the mixtures after maximal binding had been reached, a more rapid dissociation of the bound radioligand was observed, but was again incomplete (Fig. 5) . Appropriate controls were included to take into account the dilution effect of the addition of unlabeled vWF (Fig. 5) . In control mixtures incubated in the absence of excess unlabeled vWF, a slow, spontaneous dissociation of bound '25I-vWF followed the plateau of binding. Even in this case, apparently irreversible binding corresponded to 30-50% of maximal binding (Fig. 5) . This apparently irreversible binding was not related to internalization of vWF molecules, since washing of platelets in the presence of EDTA after maximal binding had been reached resulted in removal of 99% of the radioactivity previously associated to platelets.
Saturation of binding. The binding of '25I-vWF to thrombin-stimulated platelets (Fig. 6) , as well as ADPor ADP + EPI-stimulated platelets (data not shown), was saturable. This was evident after subtraction of nonspecific from total measured binding in mixtures that had been incubated with increasing concentrations of '25I-vWF and constant platelet number for 30 min. This incubation time was selected on the basis of the results shown in Figs. 2 (Fig. 7) . In some experiments, control and specific IgG, or anti-GIb and anti-GPIIb/ IIIa IgG, were added together in the same mixtures. 2'11-vWF Added (pglml) FIGURE 7 The effect of monoclonal antibodies against platelet membrane GPIb or HIb/IIIa on the specific binding of '251-vWF induced by thrombin (left panel), ristocetin (middle panel), or a combination of ADP + EPI (right panel). Platelets (108/ml) were mixed with '25I-vWF (as indicated on the abscissa) and monoclonal IgG in the following concentrations: control (B33.1; anti-HLA-DR common determinant) = 435 gg/ml; anti-GPIb (API) = 11.6 gg/ml; anti-GP HIb/IIIa (B59.2) = 298 gg/ml. The appropriate agonist (thrombin, 0.5 U/ml; ristocetin 1.5 mg/ml; ADP + EPI, 20 uM each) was then added, and after incubation for 30 Ristocetin-induced binding of '251-vWF to platelets was inhibited only when anti-GPIb antibody was present, and thrombin-induced binding when anti-GPIIb/ IlIa antibody was present, irrespective of the other monoclonal IgG added. Binding to Bernard-Soulier platelets. In the two related patients with the Bernard-Soulier syndrome studied, specific thrombin-induced binding of 125I1 vWF to ADG-washed platelets was increased, rather than decreased, when compared with normal platelets prepared under identical conditions (Fig. 8) . Preliminary studies had shown that these platelets isolated in a similar manner failed to agglutinate to and bind vWF in response to ristocetin.
Characterization of bound 125_-vWF. Analysis by SDS agarose electrophoresis of the bound ligand extracted from the platelet pellets after phase separation showed that all multimers of '251-vWF bound to platelets stimulated with the three different agonists (Fig.  9) . Moreover, decreased thrombin-and ADP + EPIinduced binding in the presence of anti-GPIIb/IIIa antibody was represented by a parallel decrease of all multimers bound and not a specific subset of them (Fig. 9 ).
DISCUSSION
Specific binding sites for vWF exist on human platelets and are expressed by different platelet agonists (2) (3) (4) (5) .
In this study we demonstrate that the ristocetin-induced binding of vWF (2) "'lIlvWF Added (Mg/ml) FIGURE 8 Specific binding of '251-vWF to thrombin (0.5 U/ ml)-stimulated platelets in two Bernard-Soulier patients and a normal control. Experimental conditions are as described in the legend to Fig. 7 , with the exception that Tyrode buffer was added instead of control monoclonal IgG. Results shown are not corrected for the increased volume of Bernard-Soulier platelets.
fore, our purpose for these studies was to verify that our binding assay with ristocetin could reproduce the results already reported in the literature (2), as indeed it did. The demonstration that thrombin (3, 4) and ADP (5) also induce binding of vWF to platelets is more recent. Therefore, we thought it appropriate to characterize extensively the binding assay performed with these agonists in order to demonstrate that the site induced fulfills the criteria for a specific binding site. The conclusion that this is the case is supported by the demonstration that the binding of vWF induced by thrombin, ADP, and ADP + EPI is time dependent, specific, and saturable. Specificity of binding is indicated by (a) the capacity of unlabeled vWF to inhibit competitively the binding of '251-vWF with the same apparent affinity; (b) the failure of other proteins, and notable all the proteins in severe von Willebrand disease serum, to compete for binding; and (c) the identification of bound material as a multimeric protein with the typical structure of plasma vWF (21) .
Fibrinogen is a likely contaminant of purified vWF preparations. We obtained direct evidence that this was not the case for the purified vWF used in these studies by demonstrating the absence of any measurable fibrinogen using a sensitive radioimmunoassay. Moreover, several observations provide indirect evidence that possible fibrinogen or fibronectin contamination cannot explain the binding observed with our purified vWF preparations. (a) EPI-stimulated platelets bind fibrinogen (28), but not fibronectin (29) nor vWF. ADP-stimulated platelets bind fibrinogen (12) and vWF, but not fibronectin (29) . Thrombin is the only effective stimulus to induce platelet binding of fibronectin (29) . (b) A combination of ADP + EPI increases the binding of vWF over that observed with ADP alone. Thrombin-induced binding, however, is more than double that observed with the combination of ADP + EPI. Thrombin-induced binding of fibrinogen, on the contrary, occurs at levels similar to those observed with ADP or ADP + EPI stimulation (30) . (c) The stoichiometries of vWF and fibrinogen binding are clearly different. Half saturation of binding occurs at -5 jg/ml of added vWF, as opposed to -60 sg/ml of added fibrinogen (12, 28, 30) . The fraction of added fibrinogen that binds to platelets corresponds to 2-3% at best (12, 28, 30) (2) . Similar results have also been observed for fibrinogen interaction with platelets (31) . Another characteristic of vWF binding to the thrombin-induced site is its partial spontaneous reversibility upon prolonged incubation. Since the levels of cyclic AMP have been shown to be important in regulating vWF binding to thrombin-stimulated platelets (3), but not to ristocetin-treated platelets (32), our findings might be related to fluctuations of intraplatelet cyclic AMP following platelet stimulation.
After extensive characterization of the platelet vWF binding site induced by thrombin, ADP, and ADP + EPI, our purpose was to evaluate whether this binding site corresponded to that induced by ristocetin. The suggestion that this might not be the case derived from (a) the different metabolic and divalent cation requirements for expression and/or function of these binding sites, as observed during the course of these studies and by others (3); (b) our recent observation that thrombininduced binding of vWF is deficient in Glanzmann thrombasthenia (4), whereas ristocetin-induced binding is normal (8) .
There is ample evidence that GPIb functions as the platelet binding site for vWF in the presence of the antibiotic ristocetin (2, (6) (7) (8) (34) have also reported studies with a different monoclonal antibody to GPIb that completely blocks ristocetin-induced binding of vWF to platelets. It is evident, however, that GPIb, or at least the epitope recognized by the antibody used in these studies and essential for ristocetin-induced binding, is not involved as part of the vWF binding site exposed on platelets stimulated by thrombin or ADP + EPI. This conclusion is further substantiated by the finding that thrombin-induced binding was increased, rather than decreased, in two Bernard-Soulier patients whose platelets had been shown in previous studies to have extremely low levels of GPIb (10) . Bernard-Soulier platelets adhere poorly to subendothelium (35) and are severely defective in their capacity of binding vWF multimers in the presence of ristocetin (8) . Hence, it has been postulated that the vWF binding sites exposed by ristocetin are involved in subendothelium-platelet interaction mediated by vWF. Following this hypothesis, the thrombin-induced binding sites for vWF are likely to be less important in this interaction, as they are normally expressed on Bernard-Soulier platelets.
We have recently described the severely deficient thrombin-induced binding of vWF to thrombasthenic platelets and suggested that the GPIIb/IIIa complex may be a component of the binding site for vWF exposed on thrombin-stimulated platelets (4) . Such an hypothesis is further supported by the studies here reported. In fact, blocking of GPIIb/IIIa by monoclonal antibodies results in reduced thrombin-induced as well as ADP + EPI-induced binding of vWF. These results suggest the existence of common mechanisms leading to the expression of vWF binding sites on platelets stimulated by these three physiological agonists, but not by ristocetin.
One of the anti-GPIIb/IIIa antibodies tested only partially blocked the platelet binding of vWF induced by thrombin, but the other was more effective in this regard. The less effective antibody might recognize an epitope of the GPIIb/IIIa complex not directly related to the binding site, and therefore interfere with vWF binding only by steric hindrance, whereas the other might recognize an epitope more closely related or correspondent to the vWF binding site.
Appropriate controls were performed to demonstrate that the effect of the monoclonal antibodies was on specific binding of vWF. This was shown by the fact that the addition of excess monoclonal IgG directed against an epitope not present on platelets had no effect on the results, thus ruling out the possibility of nonspecific effects related to interaction with the Fc receptor on platelets. Moreover, the vWF binding to thrombin-stimulated platelets in the presence of the anti-GPIb antibody corresponded to the binding that could be completely suppressed by excess unlabeled vWF. This, together with the demonstrated time-dependence and saturability, shows that thrombin-induced binding of vWF in the presence of blocked GPIb is specific. The possibility that the blocking effect of anti-GPIIb/IIIa antibodies was on the binding of contaminants present in the vWF preparations, rather than on the binding of vWF itself, is unlikely as shown by (a) the lack of any detectable contaminant, and notably fibrinogen, in the vWF preparations used; and (b) the direct demonstration that decreased binding of radiolabeled ligand in the presence of anti-GPIIb/IIIa antibodies was accompanied by a decrease in vWF multimers bound to platelets, as detected by SDS agarose electrophoresis and autoradiography after solubilization of >80% of bound ligand.
In conclusion, these studies, as well as the results previously obtained in Glanzmann thrombasthenia (4) 
